Enfusion, Inc. (NYSE:ENFN) Director Deirdre Somers Sells 1,637 Shares of Stock

Enfusion, Inc. (NYSE:ENFN) Director Deirdre Somers sold 1,637 shares of Enfusion stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $10.53, for a total transaction of $17,237.61. Following the transaction, the director now owns 41,675 shares of the company’s stock, valued at approximately $438,837.75. The trade was a 3.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Enfusion Stock Up 0.9 %

Shares of NYSE:ENFN opened at $10.91 on Thursday. The business has a fifty day simple moving average of $10.22 and a 200-day simple moving average of $9.25. Enfusion, Inc. has a 52 week low of $7.52 and a 52 week high of $11.38. The company has a market cap of $1.40 billion, a P/E ratio of 272.82, a P/E/G ratio of 3.98 and a beta of 0.95.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Stifel Nicolaus lifted their price objective on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. William Blair restated a “market perform” rating on shares of Enfusion in a research report on Monday. Finally, Piper Sandler boosted their target price on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.25.

Hedge Funds Weigh In On Enfusion

Institutional investors and hedge funds have recently bought and sold shares of the stock. Arizona State Retirement System acquired a new stake in Enfusion during the second quarter worth about $86,000. Harbor Capital Advisors Inc. boosted its position in Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after purchasing an additional 1,315 shares during the period. Belvedere Trading LLC acquired a new position in shares of Enfusion during the third quarter worth about $114,000. Paloma Partners Management Co purchased a new stake in shares of Enfusion during the 3rd quarter valued at about $157,000. Finally, The Manufacturers Life Insurance Company lifted its position in Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after acquiring an additional 4,239 shares in the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.